Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Inhibitor resistant class A beta-lactamases.

R A Bonomo¹, L B Rice

¹Geriatric CARE Center, Cleveland, OH 44120, USA. rab14@po.cwru.edu

Frontiers in Bioscience : a Journal and Virtual Library

|May 20, 1999

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

<i>Escherichia coli</i> producing AmpC DHA-1 bacteraemia in neutropenic leukemic patient: continuous infusion ceftazidime/avibactam as a carbapenem sparing regimen.

JAC-antimicrobial resistance·2025

Same author

Exploring avibactam and relebactam inhibition of <i>Klebsiella pneumoniae</i> carbapenemase D179N variant: role of the Ω loop-held deacylation water.

Antimicrobial agents and chemotherapy·2023

Same author

Acinetobacter quorum sensing contributes to inflammation-induced inhibition of orthopaedic implant osseointegration.

European cells & materials·2022

Same author

Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam.

Antimicrobial agents and chemotherapy·2022

Same author

Epidemiology and genotypic characterisation of dissemination patterns of uropathogenic Escherichia coli in a community.

Epidemiology and infection·2019

Same author

Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex <i>In Vitro</i>.

mBio·2019

Beta-lactamase inhibitors improve antibiotic effectiveness but resistance is growing. New research explores inhibitor-resistant enzymes to develop better drugs.

Area of Science:

Microbiology
Biochemistry
Pharmacology

Background:

Beta-lactamase inhibitors like clavulanic acid, tazobactam, and sulbactam are crucial for enhancing antibiotic efficacy against bacteria with class A beta-lactamases.
The emergence of inhibitor-resistant class A beta-lactamases, such as TEM and SHV variants, poses a significant threat to current antimicrobial therapies.

Purpose of the Study:

To investigate the characteristics of inhibitor-resistant class A beta-lactamases.
To understand the mechanisms behind resistance, including point mutations and hyper-production.

Main Methods:

Analysis of mutations in TEM and SHV class A beta-lactamases.
Kinetic studies comparing wild-type and resistant enzymes.
Investigation of promoter region mutations leading to enzyme overproduction.

Related Experiment Videos

Main Results:

Inhibitor-resistant beta-lactamases exhibit reduced hydrolysis of common beta-lactam antibiotics.
Point mutations in critical amino acid residues impair enzyme catalysis.
Mutations in promoter regions can lead to hyper-production, conferring high-level resistance.

Conclusions:

Understanding the microbiologic and kinetic properties of these resistant enzymes is essential.
This knowledge can guide the development of novel beta-lactam compounds and more effective inhibitors.
Combating antimicrobial resistance requires continuous research into bacterial defense mechanisms.